Reuters: Health
AstraZeneca Plc said on Wednesday it plans to sell the European and Russian rights for a schizophrenia drug to German firm Cheplapharm Arzneimittel for an upfront payment of $178 million, as the British drugmaker looks to offload older drugs.
No comments:
Post a Comment